Alembic Pharmaceuticals has received tentative USFDA approval for its generic Larotrectinib Capsules. The company is the sole first applicant, potentially securing 180 days of marketing exclusivity in the US.
Alembic Pharmaceuticals Secures Tentative USFDA Approval for Larotrectinib Capsules
Alembic Pharmaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its generic Larotrectinib Capsules, available in 25 mg and 100 mg strengths. ## What just happened The approval is for a generic version of Bayer Healthcare Pharmaceuticals Inc.'s Vitrakvi, used to treat certain solid tumors with specific gene fusions. Alembic is the sole first applicant to file an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification for this product. ## Why this matters This 'sole first applicant' status under the Hatch-Waxman Act could grant Alembic Pharmaceuticals 180 days of generic marketing exclusivity in the US upon final approval. The estimated US market for this product is US$ 91 million for the 12 months ending March 2026. ## The backstory The company has achieved 241 cumulative USFDA ANDA approvals to date, with 221 being final approvals and 20 being tentative approvals. ## What changes now The tentative approval signifies that the USFDA has reviewed the product and found it compliant with regulatory standards, pending resolution of patent and exclusivity issues. ## Risks to watch The approval is 'tentative,' meaning final commercial launch is contingent upon resolving existing patent or exclusivity disputes linked to the reference drug. ## Investor Takeaway This regulatory milestone underscores Alembic's R&D capabilities and its strategic focus on the US generic market. The potential for marketing exclusivity is a significant factor for future revenue. ## What to track next Investors should monitor future developments regarding patent resolutions and the transition from tentative to final USFDA approval for the Larotrectinib Capsules.
